Pre-made Naxitamab benchmark antibody ( Whole mAb, anti-Ganglioside GD2 therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Naxitamab biosimilar, Whole Mab: Anti-Ganglioside GD2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Naxitamab, sold under the brand name Danyelza, is an anti-cancer medication. It is a monoclonal antibody used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for people one year of age and older with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow demonstrating a partial response, minor response, or stable disease to prior therapy.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-370-1mg	1mg	3090
GMP-Bios-ab-370-10mg	10mg	Inquiry
GMP-Bios-ab-370-100mg	100mg	Inquiry
GMP-Bios-ab-370-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Naxitamab biosimilar, Whole Mab: Anti-Ganglioside GD2 therapeutic antibody
INN Name	Naxitamab
Target	Ganglioside GD2
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2018
Year Recommended	2019
Companies	Memorial Sloan-Kettering Cancer Center;Y-mAbs Therapeutics
Conditions Approved	Neuroblastoma
Conditions Active	Osteosarcoma
Conditions Discontinued	Breast cancer;Sarcoma;Small cell lung cancer
Development Tech	na